WATERTOWN, Mass.--(BUSINESS WIRE)--May. 28, 2013--
Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, today announced that Enanta management will present at two investor conferences during the month of June.
Jay R. Luly, Ph.D., President and CEO, will present a corporate overview followed by a Q&A session at the following investor conferences:
- Jefferies 2013 Healthcare Conference, Wednesday, June 5 at 11:00 a.m. ET., New York
- Wells Fargo Securities 2013 Healthcare Conference, Tuesday, June 18 at 11:10 a.m. ET., Boston
A live audio webcast and replay of the presentations can be accessed by visiting the Investor homepage section of Enanta’s website at www.enanta.com. A replay of the webcasts will be available approximately two hours following the presentations and will be archived for approximately 30 days.
About Enanta
Enanta Pharmaceuticals is a research and development-focused biotechnology company that uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs in the infectious disease field. Enanta is discovering and developing novel inhibitors designed for use against the hepatitis C virus (HCV). These inhibitors include members of the direct acting antiviral (DAA) inhibitor classes – protease (partnered with AbbVie), NS5A (partnered with Novartis) and nucleotide polymerase – as well as a host-targeted antiviral (HTA) inhibitor class targeted against cyclophilin. Additionally, Enanta has created a new class of antibiotics, called Bicyclolides, for the treatment of multi-drug resistant bacteria, with a current focus on developing an intravenous and oral treatment for hospital and community MRSA (methicillin-resistant Staphylococcus aureus) infections.
Source: Enanta Pharmaceuticals, Inc.
Investor Contact
Enanta Pharmaceuticals, Inc.
Carol Miceli, 617-607-0710
cmiceli@enanta.com